The Burden of HPV-Associated Anogenital Cancers
- 608 Downloads
The epidemiology of anogenital cancers is under going substantial change. Cervical cancer remains a major public health concern, particular in resource-limited settings. Cancers of the anus, penis, vagina and vulva are relatively uncommon cancers, but may be increasing in incidence. The change in occurrence of anogenital cancers may be due to increasing HPV transmission secondary to changes in sexual behaviour. Screening programmes and the HPV vaccine offer optimism that anogenital cancers can be prevented. This article reviews the epidemiology of anogenital cancers with a focus on Scottish data.
KeywordsHuman papillomavirus Cervical cancers Anal cancer Penile cancer Vaginal cancer Vulvar cancer
The authors acknowledge Doug Clark of NHS National Services Scotland for preparation of the Scottish Cancer Registry data presented in this article.
Compliance with Ethics Guidelines
Conflict of Interest
Katie Wakeham and Kimberley Kavanagh declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
- 1.International Agency for Research on Cancer. GLOBOCAN 2012. In: Cervical cancer estimated incidence, mortality and prevalence worldwide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 4 May 2014.
- 2.McCredie MR et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol. 2006;9(5):425–34.Google Scholar
- 3.Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine. 2006;24 Suppl 3:S11–25.Google Scholar
- 4.International Collaboration of Epidemiological Studies of Cervical Cancer. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120:885–90.Google Scholar
- 5.International Collaboration of Epidemiological Studies of Cervical Cancer. Carcinoma of the cervix and tobacco smoking: collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer. 2006;118(6):1481–95.CrossRefGoogle Scholar
- 6.Wallin KL et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer. 2002;101:371–4.Google Scholar
- 8.Castellsague X et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med. 2002;346:1105–12.Google Scholar
- 9.International Agency for Research on Cancer. World Cancer Report 2008. http://www.iarc.fr/en/publications/pdfs-online/wcr/2008/index.php. Accessed on 4 May 2014.
- 10.Information Service Division, Scotland. Cancer incidence and mortality in Scotland by site/type of cancer, sex and year of diagnosis/registration of death: 2002-2011. http://www.isdscotland.org/Health-Topics/Cancer/Cancer-Statistics/. Accessed 4 May 2014.
- 11.Information Service Division, Scotland. Scottish Cervical Screening Programme. http://www.isdscotland.org/Health-Topics/Cancer/Cervical-Screening/. Accessed on 4 May 2014.
- 14.Bray F et al. Trends in cervical squamous cell carcinoma incidence in 13 European countries: changing risk and the effects of screening. Cancer Epidemiol Biomarkers Prev. 2005;14(3):677–86.Google Scholar
- 53.Wabinga HR et al. Trends in the incidence of cancer in Kampala, Uganda 1991-2010. Int J Cancer. 2014;135(2):432–9.Google Scholar
- 54.Wabinga HR et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 2000;82:1585–92.Google Scholar
- 56.Bruni L, et al. Human papillomavirus and related diseases report. L'Hospitalet de Llobregat: ICO Information Centre on HPV and Cancer; 2014.Google Scholar
- 57.Daling JR et al. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Gynecol Oncol. 2002;84:263–70.Google Scholar
- 59.Engels EA et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–901.Google Scholar
- 60.Gunderson CC, et al. A contemporary analysis of epidemiology and management of vaginal intraepithelial neoplasia. Am J Obstet Gynecol. 2013;208:410.e1–6.Google Scholar
- 61.Gunderson CC et al. Vaginal cancer: the experience from 2 large academic centers during a 15-year period. J Low Genit Tract Dis. 2013;17:409–13.Google Scholar
- 62.Cheng D et al. Wide local excision (WLE) for vaginal intraepithelial neoplasia (VAIN). Acta Obstet Gynecol Scand. 1999;78(7):648.Google Scholar
- 63.Aho M et al. Natural history of vaginal intraepithelial neoplasia. Cancer. 1991;68(1):195.Google Scholar
- 64.Hellman K et al. Clinical and histopathologic factors related to prognosis in primary squamous cell carcinoma of the vagina. Int J Gynecol Cancer. 2006;16:1201–11.Google Scholar
- 65.Tran PT et al. Prognostic factors for outcomes and complications for primary squamous cell carcinoma of the vagina treated with radiation. Gynecol Oncol. 2007;105:641–9.Google Scholar
- 66.Joura EA et al. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J Reprod Med. 2000;45:613–5.Google Scholar
- 67.Madsen BS et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina—population-based case-control study in Denmark. J Int Cancer. 2008;122:2827–34.Google Scholar
- 68.Jones RW et al. Trends in squamous cell carcinoma of the vulva: the influence of vulvar intraepithelial neoplasia. Obstet Gynecol. 1997;90:448–52.Google Scholar
- 69.Palefsky J. Human papillomavirus-related disease in people with HIV. Curr Opin HIV AIDS. 2009;4:52–6.Google Scholar
- 70.van Seters M et al. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol Oncol. 2005;97:645–51.Google Scholar
- 71.Judson PL et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol. 2006;107:1018–22.Google Scholar
- 72.Srodon M et al. The distribution of low and high-risk HPV types in vulvar and vaginal intraepithelial neoplasia (VIN and VaIN). Am J Surg Pathol. 2006;30:1513–8.Google Scholar
- 73.Conley LJ et al. HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet. 2002;359:108–13.Google Scholar
- 74.Burger MP et al. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol. 1995;57:327–34.Google Scholar
- 75.Gadducci A et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol. 2006;60:227–41.Google Scholar
- 76.International Agency for Research on Cancer, monographs on the evaluation of carcinogenic risk to humans, 2007. In: Monograph on human papillomavirus, volume 90. http://monographs.iarc.fr/ENG/Monographs/vol90/index.php . Accessed 18 June 2014.
- 77.Clifford G et al. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24 Suppl 3:S26–34.Google Scholar
- 78.De Vuyst H et al. Prevalence of human papillomavirus in women with invasive cervical carcinoma by HIV status in Kenya and South Africa. Int J Cancer. 2012;131:949–55.Google Scholar
- 79.Houlihan CF et al. Prevalence of human papillomavirus in adolescent girls before reported sexual debut. J Infect Dis. 2014. doi: 10.1093/infdis/jiu20.
- 80.Winer RL et al. Detection of genital HPV types in fingertip samples from newly sexually active female university students. Cancer Epidemiol Biomarkers Prev. 2010;19:1682–5.Google Scholar
- 81.af Geijersstam V et al. Trends in seroprevalence of human papillomavirus type 16 among pregnant women in Stockholm, Sweden, during 1969-1989. Int J Cancer. 1998;76:341–4.Google Scholar
- 82.Laukkanen P et al. Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol. 2003;84:2105–9.Google Scholar
- 83.Mercer CH et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the national surveys of sexual attitudes and lifestyles (Natsal). Lancet. 2013;382:1781–94.Google Scholar
- 84.Kangas I et al. A comparison of sexual behaviour and attitudes of healthy adolescents in a Danish high school in 1982, 1996, and 2001. Popul Health Metrics. 2004;2:5.Google Scholar
- 85.Winer RL et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med. 2006;354:2645–54.Google Scholar
- 86.Gray RH et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis. 2010;201:1455–62.Google Scholar
- 87.Serwadda D et al. Circumcision of HIV-infected men: effects on high-risk human papillomavirus infections in a randomized trial in Rakai, Uganda. J Infect Dis. 2010;201:1463–9.Google Scholar
- 88.Kitchener HC et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672.Google Scholar
- 89.Ronco G et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524.Google Scholar
- 90.Sankaranarayanan R et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet. 2007;370:398–406.Google Scholar
- 91.Shastri SS et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ. 2005;83:186–94.Google Scholar
- 92.Franco EL et al. Chapter 20: issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24 Suppl 3:S171–7.Google Scholar
- 93.Smyczek P et al. Anal intraepithelial neoplasia: review and recommendations for screening and management. Int J STD AIDS. 2013;24(11):843–51.Google Scholar
- 95.Garland SM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928.Google Scholar
- 96.Malagon T et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12:781–9.Google Scholar
- 97.Kavanagh K et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014;110:2804–11.Google Scholar
- 98.Palefsky JM et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576–85.Google Scholar
- 99.Wigle J et al. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine. 2013;31(37):3811–7.Google Scholar
- 100.Stanley M. HPV vaccination in boys and men. Hum Vaccin Immunother. 2014. doi: 10.4161/hv.29137.
- 101.The Scottish Parliament. Petitions, PE01477: Gender neutral Human Papillomavirus vaccination, 2013.http://www.scottish.parliament.uk/GettingInvolved/Petitions/petitionPDF/PE01477.pdf. Accessed 17 June 2014.